Cross-linking Stabilizes Protein Complexes for MALDI Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing the effect of drug candidates on protein complexes, such as MALDI mass spectrometry, face challenges like dissociation of non-covalent interactions during analysis, reduced detection sensitivity for high-mass protein complexes, and lack of quantitative correlation between peak intensity and protein complex amount, making it difficult to quantify drug effects on protein-protein interactions.
Innovation Solution
A method involving incubation of drug candidates with protein complexes, followed by cross-linking to form covalently stabilized complexes, which are then analyzed using high-mass MALDI ToF mass spectrometry without digestion or fragmentation, allowing direct determination of drug effects by comparing mass peaks with a negative control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MALDI mass spectrometry is used to analyze protein complexes, then detection capability is provided, but non-covalent interactions dissociate during analysis
Solution Approach 1:
The patent applies preliminary cross-linking action before mass spectrometry analysis. Chemical cross-linking reagents are introduced to form covalent bonds between protein subunits in the complex before the analysis step, thereby stabilizing the non-covalent interactions that would otherwise dissociate during MALDI-MS analysis
Solution Approach 2:
The patent introduces chemical cross-linking reagents as intermediary substances that mediate between the protein complex and the mass spectrometry analysis. These reagents form covalent bridges between protein subunits, acting as intermediaries that preserve the complex structure during the analytical process
2Reliability
If standard MALDI mass spectrometry is used for high-mass protein complexes, then analysis is performed, but detection sensitivity is reduced
Solution Approach 1:
The patent changes the mass-to-charge ratio parameter distribution by promoting the formation of multiply charged ions through cross-linking. This shifts the detection range to more favorable m/z values that enhance sensitivity in the high-mass region, allowing better detection of large protein complexes
3Reliability
If ESI-MS is used to analyze protein complexes, then intact ions can be observed, but response factors differ for different complexes making quantification difficult
Solution Approach 1:
The patent changes the ionization state by promoting multiply charged ion formation through cross-linking. This parameter change in charge state distribution creates a more uniform response factor across different protein complexes, enabling accurate quantification by relating ion intensities to solution concentrations
4Stability of the object's composition
If cross-linking is performed before MALDI analysis, then complex stability is improved, but additional steps are required in the analysis procedure
Solution Approach 1:
The cross-linking reagents serve as intermediaries that can be easily introduced into the sample before analysis. The method integrates smoothly into the existing MALDI-MS workflow, requiring only the addition of the cross-linking step, which simplifies the overall process compared to alternative approaches
Data Source
AI summary
The invention relates to a method of using high mass matrix assisted laser desorption-ionization (MALDI) mass spectrometry for the qualitative and quantitative analysis of the effect of drug candidates on protein complexes such as protein-protein interactions in purified samples or complex biological matrices, as well as to the use of this method for lead compound optimization, drug characterization, drug manufacturing processes, and drug quality control processes, including automated high throughput applications.